{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:31:32Z","timestamp":1780612292668,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T00:00:00Z","timestamp":1598745600000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.rmr.2019.05.040","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T10:05:22Z","timestamp":1562234722000},"page":"902-905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pneumopathie infiltrative diffuse, p\u00e9ricardite et pleur\u00e9sie d\u2019hypersensibilit\u00e9 compliquant un traitement par ceritinib"],"prefix":"10.1016","volume":"36","author":[{"given":"C.-M.","family":"Gaillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Chumbi-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gaillot-Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Craighero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Devouassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kiakouama-Maleka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2019.05.040_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-016-0251-8","article-title":"Second- and third-generation ALK inhibitors for non-small cell lung cancer","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.rmr.2019.05.040_bib0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jjco\/hyx045","article-title":"Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset","volume":"47","author":"Hida","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.rmr.2019.05.040_bib0065","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1\u00a0rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2019.05.040_bib0070","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2013.07.002","article-title":"ALK inhibitors in the treatment of advanced NSCLC","volume":"40","author":"Gridelli","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.rmr.2019.05.040_bib0075","first-page":"145","article-title":"Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib","volume":"8","author":"El-Osta","year":"2015","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.rmr.2019.05.040_bib0080","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.cllc.2017.10.008","article-title":"Lung toxicity in non\u2013small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature","volume":"19","author":"Pellegrino","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.rmr.2019.05.040_bib0085","unstructured":"novartis, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS zykadia, http:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/003819\/WC500187504.pdf."},{"key":"10.1016\/j.rmr.2019.05.040_bib0090","first-page":"967","article-title":"Hypersensibilit\u00e9 aux m\u00e9dicaments","volume":"65","author":"Nicolas","year":"2015","journal-title":"Rev Prat"},{"key":"10.1016\/j.rmr.2019.05.040_bib0095","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3892\/mco.2016.838","article-title":"Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer","volume":"4","author":"Nukaga","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.rmr.2019.05.040_bib0050","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/JTO.0000000000000350","article-title":"Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib","volume":"9","author":"Awad","year":"2014","journal-title":"J Thorac Oncol"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842519302426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842519302426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:19:39Z","timestamp":1760105979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842519302426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0761842519302426"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2019.05.040","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumopathie infiltrative diffuse, p\u00e9ricardite et pleur\u00e9sie d\u2019hypersensibilit\u00e9 compliquant un traitement par ceritinib","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2019.05.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}